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Abstract Charcot-Marie-Tooth disease (CMT) refers to a ge-
netically heterogeneous group of disorders which cause a pe-
ripheral motor and sensory neuropathy. The overall preva-
lence is 1 in 2500 individuals. Mutations in the MFN2 gene
are the commonest cause for the axonal (CMT2) type. We
describe a Caucasian 5-year old girl affected by CMT2A since
the age of 2 years. She presented with unsteady gait, in-
turning of the feet and progressive foot deformities. Nerve
conduction studies suggested an axonal neuropathy and mo-
lecular testing identified a previously reported pathogenic var-
iant c.1090C > T, p.(Arg364Trp) in the MFN2 gene. This
variant was also detected in a mosaic state in blood and saliva
by Sanger sequencing in her subjectively healthy father. Next
generation sequencing showed that the level of mosaicism
was 21% in blood and 24% in saliva. A high recurrence risk
was given because the father had proven somatic mosaicism
and an affected child implying gonadal mosaicism. The par-
ents were referred for pre-implantation genetic diagnosis. To
the best of our knowledge, this is the first reported case of
somatic mosaicism for MFN2. This study has important im-
plications for genetic counselling in families with CMT2A.
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Introduction
Charcot-Marie-Tooth (CMT) disease refers to a heteroge-
neous group of hereditary disorders which cause a peripheral
motor and sensory neuropathy. The overall prevalence is ap-
proximately 1 in 2500 [1]. They are also genetically hetero-
geneous with over 60 reported genes [2]. Autosomal domi-
nant, autosomal recessive and X-linked inheritance have been
described. CMT can also be classified on the basis of nerve
conduction velocity into demyelinating (CMT1) and axonal
(CMT2) types.
Charcot-Marie-Tooth disease type 2A is caused by mu-
tations in the MFN2 (mitofusin 2) gene (OMIM 608507).
Autosomal dominant inheritance or de novo dominant mu-
tations are reported in most families [3, 4]. Autosomal re-
cessive inheritance or semi-dominant inheritance has also
been reported, mostly with a more severe phenotype [5, 6].
CMT2A caused by heterozygous mutations in MFN2 has a
variable phenotype with an early onset form with age at
onset <10 years (mean age 3.5 years) and a late onset form
with age at onset > = 10 years (mean age 20.5 years) [3].
The early onset form is more common and usually has a
more severe phenotype [3]. CMT2A is characterised by
earlier and more severe involvement of the lower extrem-
ities, more severe motor than sensory involvement and
normal or slightly decreased nerve conduction velocities.
Some patients have additional features of optic atrophy
and/or spinal cord abnormalities [4].
Mosaicism occurs when an individual who has devel-
oped from a single fertilised egg has two or more cell lines
which are discordant for a genetic feature [7]. This could
be a chromosomal abnormality, for example in mosaic
Trisomy 21, or it could be a sequence variant. The occur-
rence of families with more than one affected child for an
apparently de novo dominant or X-linked condition (i.e.
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where the mutation was not detected on testing parental
samples) can be explained by gonadal (or germline) mosa-
icism. Individuals may have gonadal mosaicism only, or
may have somatic and gonadal mosaicism. Somatic mosa-
icism is being increasingly detected as a result of next
generation sequencing [8].
Materials and Methods
The family was ascertained through referral to the East Anglian
Medical Genetics Service. Informed consent for publication
was obtained. The proband and her father were assessed by
the neurologists (GA and TDG). Electrophysiology studies
(electromyography and nerve conduction studies) were per-
formed in the proband. A peripheral blood DNA sample from
the proband was tested for copy number changes on chromo-
some 17 using the Agilent ISCA 8x60K v2 array and
CytoGenomics software, Edition 2.5.8.11 (Build 37). This
showed she did not have the CMT1A duplication or hereditary
neuropathy with liability to pressure palsies (HNPP) deletion.
Next generation sequencing of the coding region (+/− 5 bp)
was performed using the Illumina TruSight One sequencing
panel for the following genes: AARS (NM_001605.2);
ARHGEF10 (NM_014629.2); ATL1 (NM_015915.4);
CTDP1 (NM_004715.4); DNM2 (NM_001005361.2);
DNMT1 (NM_001130823.1); DST (NM_015548.4);
DYNC1H1 (NM_001376.4); EGR2 (NM_000399.3);
FAM134B (NM_001034850.2); FBLN5 (NM_006329.3);
FGD4 (NM_139241.2); FIG4 (NM_014845.5); GAN
(NM_022041.3); GARS (NM_002047.2); GDAP1
(NM_018972.2); GJB1 (NM_000166.5); HOXD10
(NM_002148.3); HSPB1 (NM_001540.3); HSPB8
(NM_014365.2); IKBKAP (NM_003640.3); KARS
(NM_001130089.1); KIF1A (NM_001244008.1); KIF1B
(NM_015074.3); LITAF (NM_004862.3); LMNA
(NM_170707.3); LRSAM1 (NM_138361.5); MED25
(NM_030973 .3 ) ; MFN2 (NM_014874 .3 ) ; MPZ
(NM_000530.6); MTMR14 (NM_001077525.2); MTMR2
(NM_016156.5) ; NDRG1 (NM_006096.3) ; NGF
(NM_002506.2); NTRK1 (NM_002529.3); PMP22
(NM_000304 .2 ) ; PRPS1 (NM_002764 .3 ) ; PRX
(NM_181882.2); RAB7A (NM_004637.5); REEP1
(NM_022912.2); SBF2 (NM_030962.3); SH3TC2
(NM_024577.3); SLC12A6 (NM_133647.1); SOX10
(NM_006941.3); SPTLC1 (NM_006415.2); SPTLC2
(NM_004863.3); TRPV4 (NM_021625.4); WNK1
(NM_001184985.1); YARS (NM_003680.3). 99.2% of the tar-
get sequence within this panel was sequenced to a depth of 20
fold or more, with analytical sensitivity of 98.3% - 100% (95%
Confidence Intervals).
Sanger sequencing with fluorescence sequence analysis
was performed in peripheral blood samples from both parents
and a saliva sample from the proband’s father. Next generation
Fig. 1 Clinical photographs
showing muscle atrophy and foot
deformities in the proband aged
5 years, and classical pes cavus
with normal muscle bulk in her
father aged 30 years
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sequence analysis of the PCR product containing the patho-
genic variant was subsequently performed in the father to
quantify the level of mosaicism.
Clinical Report
A four-year old, first born girl of an unrelated Caucasian couple
was referred with gait abnormalities and progressively worsen-
ing foot deformities. The pregnancy and birth history was nor-
mal. She crawled at 6 months and walked at 12 months but her
gait remained unsteady with recurrent falls and trips, particular-
ly in the mornings. Progressive in-turning of her left foot was
noted from age two and a half years and she was referred for
physiotherapy. Physiotherapy review at age 3 ½ years revealed
that she was unable to run or walk long distances (necessitating
wheelchair use) and could only get up off the floor with half-
kneeling. Parents also gave a history of difficulty climbing stairs
and recurrent leg pain. There were no concerns about her upper
limb function or power and speech and language development
was normal. There were no swallowing difficulties or salivary
drooling. There was no history of neuro-regression or seizures
and no concerns regarding hearing or vision.
Head circumference was 49.5 cm (50th centile). She was
noted to be hypermobile with Beighton score 5/9 and signif-
icant in-rolling of her left and right feet (L> > R). There was
good antigravity power in her upper and lower limbs. Deep
tendon reflexes were present in upper and lower limbs.
Gower’s manoeuvre was negative. She walked with dystonic
posturing of both feet and could not jump high. There was no
dysarthria and no dysmetria; cranial nerve examination was
normal with no ophthalmoplegia or ptosis.
Blood tests showed normal CK, lactate and acylcarnitine.
Nerve conduction studies at age 3 ½ showed absent sensory
and motor responses in the legs (tibial, common peroneal and








Fig. 2 Pedigree and screenshot of sequencing data from Mutation Surveyor, showing the reference sequence, proband, father (peripheral blood) and
mother. The c.1090C > T, p.(Arg364Trp) heterozygous variant is seen in the proband, and at a level of approximately 20% in her father
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interference pattern with no spontaneous activity in the motor
units tested (tibialis anterior), suggestive of a severe axonal
neuronopathy However motor nerve conduction studies in
upper limbs was normal (58.8 m/s) which also raised the pos-
sibility of a spinal cord pathology but the MRI spine was
normal. MRI of the brain and X-ray of the lower legs and hips
were also undertaken and were normal.
The in-turning of her left foot developed rapidly to a quite
marked equinovalgus deformity with marked forefoot meta-
tarsal plantar flexion. This was treated with ankle foot orthoses
and serial castings. Figure 1 shows clinical photographs of her
lower legs aged 5 years.
Genetic testing was performed for a panel of genes associ-
ated with CMT. A previously reported pathogenic variant [9,
10] was detected in the MFN2 gene c.1090C > T,
p.(Arg364Trp). This missense mutation affects a highly con-
served amino acid and there is a moderate physicochemical
difference between the arginine and tryptophan amino acids.
Individuals with this mutation have been reported both with
and without optic atrophy. No other variants were found.
Subsequent ophthalmology review was normal and annual
ophthalmology follow up was arranged.
There was no reported family history of CMT. Both parents
were keen runners. On initial examination, high arched feet
were noted in her 30-year old father (see clinical photographs
in Fig. 1). Testing of parental blood samples by fluorescent
sequence analysis detected the familialMFN2mutation in her
father at a low level of approximately 20% suggestive of mo-
saicism. Figure 2 shows the pedigree and Sanger sequencing
data. The mutation was also detected in his saliva sample at a
low level. Next generation sequence analysis was used to
quantify the level of mosaicism and showed a level of 21%
in blood and 24% in saliva. This is shown in Fig. 3.
On review, the father had normal motor milestones and had
been a sporty child. He had been a member of the armed
forces and enjoyed running as a hobby. On examination, he
had classical pes cavus with callus formation on the outer
aspect of the balls of his feet. He had no demonstrable weak-
ness, reflexes were preserved. Sensory examination revealed
reduced pinprick to mid-foot bilaterally and reduced vibration
sense to the ankles. Ophthalmology review was normal.
The parents were advised that there was a high recurrence
risk (up to 50%) in subsequent pregnancies. After discussion
of the reproductive options, the parents were referred for pre-
implantation genetic diagnosis.
Discussion
Mutations in MFN2 are the commonest genetic cause for ax-
onal CMT. The proband showed typical features for the early
onset form of the condition [3, 4]. Two recent studies of pa-
tients with CMT2A have revealed two patients with presumed





Fig. 3 Integrative Genomics Viewer (IGV) screenshot of the c.1090C > TMFN2 pathogenic variant. (a) blood DNA sample and (b) saliva DNA sample
from patient’s father. The level of mosaicism detected is 21% in the peripheral blood sample and 24% in the saliva sample
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43 French patients with CMT2Awere affected with early on-
set peripheral neuropathy and optic atrophy. A novel patho-
genic missense variant (c.775C > T, p.(Arg259Cys) was de-
tected in both siblings but not in their clinically unaffected
parents [4]. A study of Czech hereditary motor and sensory
neuropathy type II patients detected 8 pathogenic MFN2 mu-
tations, including two sisters affected with axonal CMT neu-
ropathy. A novel pathogenic missense variant c.314C > G,
p.(Thr105Arg) was detected in both sisters but not observed
in their clinically unaffected parents [11]. To the best of our
knowledge, somatic mosaicism has not been previously re-
ported in CMT2A.
The proband’s mosaic father showed minimal clinical fea-
tures of CMT. There is considerable variability is seen in
dominantly inherited CMT2A, with some patients having a
later onset, milder form of the disease [3, 4]. However, his
very mild features are most likely to be explained by the so-
matic mosaicism.
Mosaicism has been previously reported in other forms of
CMT, with a very variable clinical phenotype including
asymptomatic with normal neurophysiology studies [12], sub-
clinical disease [13], mild clinical disease [14–16] and typical
presentations of CMT1A with somatic mosaicism found on
genetic testing [17–19]. The mutations, level of mosaicism,
Table 1 Summary of mutations, level of mosaicism, clinical features and neurophysiology findings in individuals with mosaic CMT
Reference Gene Mutation % mosaicism Reason for
ascertainment
Clinical Features Neurophysiology




Affected child Bilateral pes cavus and reduced
sensation in feet aged 30
Not done
Sorour PMP22 Duplication 47.6% (blood) Affected child Clawing of toes and clumsiness
since childhood, unsteadiness
of gait from 40 years, difficulty













Clinical CMT Bilateral pes cavus, mild distal
weakness of arms and legs,
absent reflexes, sensory
disturbance distal to elbow and
knee at age 25
Motor NCV from median, ulnar
and tibial nerves 18-20 m/s
No sensory action potential
could be recorded from sural,
radial or median nerves
Rautenstrauss PMP22 Duplication 60% blood 88%
nerve tissue
72% muscle
Clinical CMT Signs and symptoms of a
demyelinating neuropathy
aged 4
Grehl PMP22 Duplication 49% blood 74%
sural nerve
Clinical CMT Generalised weakness arms and
legs from age 21, burning pains
in shoulders, hands and feet,
bilateral pes cavus, mild
distally pronounced weakness
in arms and legs, sensory
disturbance distal to elbow and
knee
Motor NCV from median, ulnar
and tibial nerves 18-20 m/s
No sensory action potential
could be recorded from sural,
radial or median nerves
Taioli PMP22 c.117G > C,
p.(Trp39Cys)
20% (blood) 2 affected
children
Subclinical age 29 Pes cavus,
decreased ankle jerk reflexes
and vibration sensation in legs
Slight reduction in sural nerve
action potentials




Motor NCV from median
43.9 m/s, ulnar 52.9, tibial
33.3.
Kochanski GJB1 p. Glu208Lys Not stated Affected
grandson
Mild clinical CMT Unable to












Bilateral carpal tunnel syndrome
age 39 Absent ankle jerk
reflexes Mild stocking
distribution pin hypoaesthesia
Ulnar, deep peroneal, tibial
motor NCS normal, absent
superficial peroneal SNAP,
low amplitude sural SNAP








Asymptomatic. Pes planus. Normal
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clinical features and neurophysiology findings from the liter-
ature are summarised Table 1.
Individuals with mild or subclinical CMT due to somatic
mosaicism who have been ascertained through an affected
child (or grandchild) have been described for CMT1A [16] ,
CMTX1 [13, 14], and CMT1E [15].
A family with CMT1B has been described with two severe-
ly affected sisters. A mutation in MPZ was found in both af-
fected sisters and in mosaic form in their mother (20% in blood,
30% in skin, buccal epithelium and hair) who was clinically
unaffected with normal neurophysiology studies [12].
Three cases of somatic mosaicism for the PMP22 duplica-
tion with clinical findings typical for CMT1 have been de-
scribed [16–18]. The level of mosaicism was fairly high in
these individuals (range 40–88%). A man with mosaic
CMTX1 has also been described who presented with symp-
toms of bilateral carpel tunnel syndrome [20].
The level of mosaicism detected in blood and saliva in the
proband’s father was quite low (at around 20%). The similar
levels of mosaicism found in blood and saliva suggest that the
mosaic mutation happened early in embryogenesis since it is
found in both ectodermal and mesodermal tissue. However, a
nerve biopsywas not undertaken, so it is possible that the level
of mosaicism in the neurons and/or Schwann cells may be
higher. This could explain why he has foot deformities despite
the low level of mosaicism. It has been recognised that it is
difficult to predict disease severity in mosaic disorders [8].
The family which we have described highlights the need
for parental testing in order to give reliable information about
recurrence risk. The diagnosis of mosaic CMT2Awould have
been missed on the basis of family history without molecular
testing. As the father has proven somatic mosaicism and an
affected child, gonadal mosaicism is assumed. Estimating the
recurrence risk in this situation is challenging. The family
were counselled for a high risk of ‘up to 50%’ risk.
Next generation sequencing is likely to detect lower levels
of mosaicism. It has been suggested that deep sequencing of
blood for pathogenic apparently de novo mutations seen in
children could be used to pick up low level mosaicism [21].
Families with no evidence of mosaicism would have a < 1%
recurrence risk, but those with low level mosaicism would
have a significantly higher risk.
Next generation sequencing was used to quantify the level
of mosaicism in the father’s blood and saliva samples with
greater accuracy than estimating the level from Sanger se-
quencing. However, we do not yet have a way of estimating
recurrence risks based on the observed level of mosaicism.
Further studies are needed to determine the most effective
ways of estimating the recurrence risk and communicating
the information to families.
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